Compare MDXG & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDXG | CADL |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.2M | 578.8M |
| IPO Year | 2007 | 2021 |
| Metric | MDXG | CADL |
|---|---|---|
| Price | $3.68 | $8.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $9.00 | ★ $19.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.29 | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,630,000.00 | $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.99 | N/A |
| 52 Week Low | $3.03 | $4.35 |
| 52 Week High | $7.99 | $9.57 |
| Indicator | MDXG | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 55.87 |
| Support Level | $3.47 | $4.80 |
| Resistance Level | $3.84 | $9.42 |
| Average True Range (ATR) | 0.13 | 0.61 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 52.50 | 37.20 |
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.